All In Biotech

Drug Trial Radar · NCT04370587

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 17, 2020

Primary completion

Sep 22, 2026

Study completion Jan 10, 2027

Sponsor

Lead sponsor
ImmVira Pharma Co. LtdIndustry
Sponsor type
Industry
First posted
May 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Conditions

  • Solid Tumor
  • Melanoma
  • HNSCC
  • Sarcoma
  • Squamous Cell Carcinoma
  • NSCLC

Interventions

  • T3011Biological

    T3011 will be administered up to 4mL as an intratumoral injection given Q2W.

  • T3011 + pembrolizumabCombination product

    T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of escalating doses T3011Time frame: Up to 2 years from first dose of T3011
  2. To determine the dose(s) of T3011 to be examined in Phase 2aTime frame: Through the first two T3011 injections (approximately 28 days)
  3. Safety and tolerability of T3011 dose(s) selected from Phase 1 in disease specific cohortsTime frame: Up to 2 years from first dose of T3011
  4. Characterize the safety and tolerability of T3011 in combination with pembrolizumabTime frame: Up to 2 years from first dose of T3011
  5. Characterize the safety and tolerability of T3011 in combination with pembrolizumab in participants who progress on T3011 aloneTime frame: Up to 2 years from first dose of T3011

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Completed

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Southern Oncology

    Bedford Park, Australia · Recruiting

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Australia · Recruiting

  • The Alfred

    Melbourne, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.